Expert Profile

Share QR code Edit Profile

Charles Heine

Prg Dir & Res Aso Prof

MD-INST FOR THERAPEUTIC INNOV | COLLEGE-MEDICINE

View:

Select
All (all in one) Research Terms and Keywords Publications Network Websites Contact

All
Research
Publications
Network
Websites
Contact

Research Terms & Keywords

Research Terms

Medical Sciences

Industries

Health Care

Research Projects

Ends

Title

04-2027

Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei

DEFENSE THREAT REDUCTION AGENC

09-2024

Battelle Subcontract 778380 SAB Year 1 Battelle Subcontract 778380 SAB Year 1

BATTELLE MEMORIAL INS

09-2024

Battelle Subcontract 778380 SAB Year 1 Battelle Subcontract 778380 SAB Year 1

DEFENSE THREAT REDUCTION AGENC

03-2024

In Vitro Microbiological Evaluations of Antibody-Drug Conjugates (ADCs) Against Category A and B Bacterial Pathogen Panels In Vitro Microbiological Evaluations of Antibody-Drug Conjugates (ADCs) Against Category A and B Bacterial Pathogen Panels

NATL INST OF HLTH NIAI

07-2023

Merck Study Agreement Merck Study Agreement

MERCK SHARP & DOHME CORP

09-2022

Evaluation of antimicrobial peptides for Biodefense Evaluation of antimicrobial peptides for Biodefense

DEFENSE THREAT REDUCTION AGENC

09-2022

Evaluation of antimicrobial peptides for Biodefense Evaluation of antimicrobial peptides for Biodefense

UNIV OF TEXAS AUSTI

08-2022

In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens

NABRIVA THERAPEUTICS

06-2022

Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4 Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4

NABRIVA THERAPEUTICS

03-2022

In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels

PROKARYOTICS

12-2021

Project Bioshield Project Bioshield

SPERO THERAPEUTICS

06-2021

Evaluation of air purification methods for SARS-CoV-2 Evaluation of air purification methods for SARS-CoV-2

HELEN OF TROY

05-2021

Teixobactin Development for Anthrax Teixobactin Development for Anthrax

NATL INST OF HLTH NIAI

11-2020

MICs for Wockhardt WCK-5222 MICs for Wockhardt WCK-5222

WOCKHARDT BIO AG

10-2020

In vitro testing of the 40 isolate panel of B. pseudomallei isolates In vitro testing of the 40 isolate panel of B. pseudomallei isolates

DEFENSE THREAT REDUCTION AGENC

10-2020

In vitro testing of the 40 isolate panel of B. pseudomallei isolates In vitro testing of the 40 isolate panel of B. pseudomallei isolates

VENATORX PHARMACEUTICALS

07-2020

KBP Biosciences Research Agreement - In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens KBP Biosciences Research Agreement - In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens

KBP BIOSCIENCES USA

08-2019

EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study

DEFENSE THREAT REDUCTION AGENC

08-2019

EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study

EMERGENT BIOSOLUTIONS

08-2019

EPDG-15-GC072-S-0001 Task 4.7 PK Study EPDG-15-GC072-S-0001 Task 4.7 PK Study

DEFENSE THREAT REDUCTION AGENC

08-2019

EPDG-15-GC072-S-0001 Task 4.7 PK Study EPDG-15-GC072-S-0001 Task 4.7 PK Study

EMERGENT BIOSOLUTIONS

04-2019

In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens

NATL INST OF HLTH NIAI

04-2019

In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens

SPERO THERAPEUTICS

03-2019

Confirmatory Efficacy Study in Bp Infected Mice Confirmatory Efficacy Study in Bp Infected Mice

DEFENSE THREAT REDUCTION AGENC

03-2019

Confirmatory Efficacy Study in Bp Infected Mice Confirmatory Efficacy Study in Bp Infected Mice

EMERGENT BIOSOLUTIONS

10-2018

Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model

DEFENSE THREAT REDUCTION AGENC

10-2018

EMERGENT BIOSOLUTIONS

09-2018

Pharmacokinetic analysis of nonhuman primate data for US Army######### Pharmacokinetic analysis of nonhuman primate data for US Army#########

US ARMY MED RES ACQUISITIO

06-2018

Evaluation of single and twice daily dosing of EBX-205 on survival of mice following aerosol exposure to B.pseudomallei 1026b Evaluation of single and twice daily dosing of EBX-205 on survival of mice following aerosol exposure to B.pseudomallei 1026b

EMERGENT BIOSOLUTIONS

02-2018

MIC90 determination of 2 ?-lactam inhancer antibacterial compounds from Wockhardt against sets of 30 strains each of Yersinia pestis, Francisella tularensis, Burkholderia mallei(12 strains) and Burkholderia pseudomallei. MIC90 determination of 2 ?-lactam inhancer antibacterial compounds from Wockhardt against sets of 30 strains each of Yersinia pestis, Francisella tularensis, Burkholderia mallei(12 strains) and Burkholderia pseudomallei.

WOCKHARDT BIO AG

01-2018

Evaluation of EBX-205 against of B. Pseudomallei in virto Evaluation of EBX-205 against of B. Pseudomallei in virto

EMERGENT BIOSOLUTIONS

01-2018

Exhibit N - MIC testing of BSC 3 extended MIC Panel in connection with Achaogen#s C-Scape project as outlined in University of Florida proposal #ITI Antibiotic Susceptibility Determinations# Exhibit N - MIC testing of BSC 3 extended MIC Panel in connection with Achaogen#s C-Scape project as outlined in University of Florida proposal #ITI Antibiotic Susceptibility Determinations#

ACHAOGEN

01-2018

ITI Antibiotic Susceptibility Determinations ITI Antibiotic Susceptibility Determinations

ACHAOGEN

01-2018

ANTIBIOTIC SUSCEPTIBILITY AND SPONTANEOUS RESISTANCE DEVELOPMENT FOR VARIOUS ISOLATES OF B. PSEUDOMALLEI ANTIBIOTIC SUSCEPTIBILITY AND SPONTANEOUS RESISTANCE DEVELOPMENT FOR VARIOUS ISOLATES OF B. PSEUDOMALLEI

DEFENSE THREAT REDUCTION AGENC

01-2018

EMERGENT BIOSOLUTIONS

12-2017

Evaluation of EBX-205 dose to survival in mice following aerosol exposure to B. pseudomallei 1026b Evaluation of EBX-205 dose to survival in mice following aerosol exposure to B. pseudomallei 1026b

EMERGENT BIOSOLUTIONS

12-2017

HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents

EMERGENT BIOSOLUTIONS

12-2017

EVOLVA SA

12-2017

US DEPT OF DEFENS

08-2017

Salary for protocol development and ACURO review Salary for protocol development and ACURO review

DEFENSE THREAT REDUCTION AGENC

08-2017

Salary for protocol development and ACURO review Salary for protocol development and ACURO review

EMERGENT BIOSOLUTIONS

07-2017

In Vitro Antibiotic Therapeutic Services in Support of protocol #AP-10-047G: Pharmokinetic and pharacodynamic analyses of intravenous Moxifloxican in Non-Human Primates using appropriate computer programs. In Vitro Antibiotic Therapeutic Services in Support of protocol #AP-10-047G: Pharmokinetic and pharacodynamic analyses of intravenous Moxifloxican in Non-Human Primates using appropriate computer programs.

US ARMY MED RES ACQUISITIO

05-2017

WITI Antibiotic Susceptibility Determinations WITI Antibiotic Susceptibility Determinations

ACHAOGEN

12-2016

Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses

DEFENSE THREAT REDUCTION AGENC

12-2016

Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses

EMERGENT BIOSOLUTIONS

04-2016

EVALUATION OF THE POTENTIAL OF GSK2140944 IN THE VIVO MURINEINHALATIONAL MODELS FOR YERSINIA PESTIS: Study #1 EVALUATION OF THE POTENTIAL OF GSK2140944 IN THE VIVO MURINEINHALATIONAL MODELS FOR YERSINIA PESTIS: Study #1

GLAXO SMITHKLIN

04-2016

US DEPT OF DEFENS

12-2015

Tetraphase MSA TP-271 Tetraphase MSA TP-271

CUBRC

11-2015

GSK BARDA Evaluation of GSK2251052 GSK BARDA Evaluation of GSK2251052

GLAXO SMITHKLIN

11-2015

Battelle Rempex/BARDA - TOA Battelle Rempex/BARDA - TOA

BATTELLE MEMORIAL INS

10-2015

Evaluation of synergistic activity and efficacy of combi Evaluation of synergistic activity and efficacy of combi

CTRS FOR DISEASE CONTROL & PREVENTIO

05-2015

CEMPRA: MIC/MBCs and Time-Kill kinetics CEMPRA: MIC/MBCs and Time-Kill kinetics

CEMPRA PHARMACEUTICALS INC

01-2015

MIC determination of 15 antibacterial compounds MIC determination of 15 antibacterial compounds

ACTELION PHARMACEUTICALS LTD

01-2015

Wockhardt Antibiotic Susceptibilities- Initial Screen Wockhardt Antibiotic Susceptibilities- Initial Screen

WOCKHARDT BIO AG

12-2012

Trius NIH NIAID SOW 2 Trius NIH NIAID SOW 2

TRIUS THERAPEUTIC

12-2012

Trius NIH NIAID SOW3 Trius NIH NIAID SOW3

TRIUS THERAPEUTIC

09-2012

SOW D Task 1: Achaogen BARDA ACHN-490 Development SOW D Task 1: Achaogen BARDA ACHN-490 Development

ACHAOGEN

09-2012

SOW F Task 3: Achaogen BARDA ACHN-490 Development SOW F Task 3: Achaogen BARDA ACHN-490 Development

ACHAOGEN

09-2012

SOW G Task 4: Achaogen BARDA ACHN-490 Development SOW G Task 4: Achaogen BARDA ACHN-490 Development

ACHAOGEN

Publications

OpenAlex
Search Engines

Last updated on 7/24/25. See our OpenAlex FAQ for more about this data.

Search Google Scholar for Charles Heine

OpenAlex Works Search

Co-Investigator Network

Inactive Expert

George Drusano

Dir & Prof

University of Florida

Md-Molecular Gentcs - Microbio, College-Medicine

Ashley Brown

Prg Dir & Aso Prof

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

ashleybrown@ufl.edu

Arnold Louie

Aso Prg Dir & Prof

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

alouie@ufl.edu

Apichai Tuanyok

Associate Professor

University of Florida

Infectious Diseases and Pathology, University Of Florida College Of Veterinary Medicine

tuanyok@ufl.edu

Inactive Expert

Herbert Schweizer

Co Prof

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

Bret Purcell

Interim Director

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

bret.purcell@medicine.ufl.edu

Expertnet Author Network

Experts within Florida Expertnet that have co-authored works with Charles Heine.

Ayalew Mergia

Professor

University of Florida

Vm-Infect Disease & Immunology, College-Veterinary Med

mergiaa@ufl.edu

Works Co-Authored: 60

Inactive Expert

George Drusano

Dir & Prof

University of Florida

Md-Molecular Gentcs - Microbio, College-Medicine

Works Co-Authored: 439

Arnold Louie

Aso Prg Dir & Prof

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

alouie@ufl.edu

Works Co-Authored: 136

Inactive Expert

Gregory Hurteau

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

Works Co-Authored: 1

Inactive Expert

David Brown

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

Works Co-Authored: 28

Apichai Tuanyok

Associate Professor

University of Florida

Infectious Diseases and Pathology, University Of Florida College Of Veterinary Medicine

tuanyok@ufl.edu

Works Co-Authored: 101

Inactive Expert

Herbert Schweizer

Co Prof

University of Florida

Md-Inst For Therapeutic Innov, College-Medicine

Works Co-Authored: 23

Kuttichantran Subramaniam

Associate Professor; Epi Director Of The Aquatic Pathobiology Lab and Epi Director Of The High-Throughput Sequencing Core

University of Florida

Vm-Infect Disease & Immunology, College-Veterinary Med

kuttichantran@ufl.edu

Works Co-Authored: 122

Inactive Expert

Nimra Khalid

Graduate Assistant - Teaching

University of Florida

Vm-Infect Disease & Immunology, College-Veterinary Med

Works Co-Authored: 2

Inactive Expert

Aria Eshraghi

Assistant Professor

University of Florida

Vm-Infect Disease & Immunology, College-Veterinary Med

Works Co-Authored: 2

Websites

ORCID 0009-0002-4746-4892

OpenAlex Works Search

Search Google Scholar for Charles Heine

Contact Information

henry.heine@medicine.ufl.edu

4073137062

ITI
RESEARCH ACADEMIC CENTER AT LAKE NONA
6550 SANGER RD
ORLANDO, FL 328277445

Profile QR code

What is this?

Charles Heine

Prg Dir & Res Aso Prof

MD-INST FOR THERAPEUTIC INNOV | COLLEGE-MEDICINE

Research Terms & Keywords

Research Projects

Publications

Co-Investigator Network

Expertnet Author Network

Websites

Contact Information

About

Discover

Connect

Keyword Search

Browse by STEM